Search Results
246 Results Found for “secondary care”
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...
New interim data from OUTSTEP 1 reveal high levels of patient satisfaction with injectable semaglutide and underscore the importance of understanding patient experiences beyond clinical trials. “While still endorsing the ‘my responsibility only’ narrative, we are learning that a new attitude ...
In this interview, Diana Isaacs shares her highlights from the 2026 AACE Annual Meeting, discussing key advances in diabetes management, obesity treatment and diabetes technology, alongside emerging priorities for future endocrinology research and guideline development.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1RA-based therapies are currently considered to be one of the most attractive classes of medications for managing type 2 diabetes (T2D) because of their impressive weight loss properties, glycated haemoglobin (HbA1c) ...
New data presented at the Advanced Technologies & Treatments for Diabetes 2026 highlight a shift in diabetes care beyond glucose control alone. Emerging evidence supports the growing role of incretin-based therapies such as semaglutide, alongside advances in continuous glucose monitoring systems including Dexcom G7 and Freestyle Libre 3. Together, these innovations demonstrate meaningful improvements in glycemic outcomes, cardiometabolic risk, and patient behaviors, signaling a move toward more personalized, integrated approaches to diabetes management across both type 1 and type 2 diabetes.
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
The significance of osteoporosis and fragility fractures in individuals with chronic kidney disease (CKD) is becoming increasingly recognized as a major contributor to disability, hospital admissions and mortality. In CKD, bone fragility is worsened by the complex interactions of metabolic ...
Highlights Autoantibodies refine autoimmune thyroid disorder diagnosis and risk. Thyroid-stimulating hormone receptor antibody predicts relapse, severity and foetal impact. Thyroid peroxidase antibody and thyroglobulin antibody linked to fertility outcomes. Novel antibodies expand thyroid autoimmunity scope. The interplay between immunology and ...
The AASLD 2025 Liver Meeting® (7–11 November, Washington, D.C., USA) delivered a breadth of early- and late-phase data across metabolic liver disease, cholestatic conditions, liver failure, and rare liver diseases. This year’s findings reflected a rapidly evolving therapeutic landscape, with meaningful progress in mechanistic understanding, emerging signals of disease modification, and increasing momentum toward more precise, combination-oriented strategies across multiple liver conditions.
Post-bariatric weight regain is a major clinical challenge. In the BARI-STEP trial, semaglutide 2.4 mg weekly led to substantial, sustained weight loss and improved cardiometabolic health. Dr Janine Makarondis discusses the findings and the potential of GLP-1 therapy in this patient population.
Gestational diabetes (GD) is a heterogeneous disorder that arises when pancreatic insulin secretion fails to compensate for the insulin resistance of pregnancy. A disbalance in either component, insufficient secretion or excessive resistance, can lead to GD and reflects its variable ...
Dr Peter Gillard discusses results from the RADIANT extension study, showing sustained benefits of the Omnipod 5 AID system for people with type 1 diabetes.
Dr Thinzar Min discusses how the Enhanced Liver Fibrosis (ELF) test could help detect liver fibrosis and assess cardiovascular risk in people with type 2 diabetes.
Hyponatraemia is primarily a disorder of water balance or distribution, characterized by serum sodium (Nas) levels less than 135 mmol/L.1 Hyponatraemia is the most common electrolyte disorder among elderly patients and is associated with increased mortality rates and longer hospital ...
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
Article Highlights Early use of sodium–glucose co-transporter-2 inhibitors following myocardial infarction was associated with the following factors: Lower hospitalization for heart failure (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62–0.90; p=0.002). Similar cardiovascular deaths (OR: 1.04; 95% CI: 0.83–1.30; p=0.76). Similar all-cause mortality (OR: 1.00; 95% ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
